Compare AbbVie Inc (ABBV) vs Kroger Co (KR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Kroger Co — how do they compare? AbbVie Inc trades at $253.95 (market cap $449.91B), while Kroger Co trades at $59.2 (market cap $35.86B). The key difference: AbbVie Inc is far larger — about 12.5× Kroger Co's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | KR | |
|---|---|---|
Market Cap | $449.91B | $35.86B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $75.60 |
52-Week Low | $184.85 | $55.53 |
Enterprise Value | $513.38B | $55.96B |
Dividend Yield | 2.72% | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Kroger (KR) trades at $58.54, up 0.55% today, with a bearish technical signal but strong analyst consensus. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026. The company announced a $1.65 billion acquisition of Giant Eagle, expanding its Midwest footprint. Cash flow improved in 2025 with net cash flow of $2.08 billion, though net income margin remains thin at 0.71%.
Outlook is cautiously optimistic with a $67.29 price target, but risks include competitive pressures and rising debt. The stock offers growth through strategic acquisitions and dividend hikes, yet faces margin compression and integration challenges from recent deals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
